Compare VERU & ELWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | ELWT |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 46.4M |
| IPO Year | 1996 | 2025 |
| Metric | VERU | ELWT |
|---|---|---|
| Price | $2.63 | $8.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $12.00 |
| AVG Volume (30 Days) | ★ 278.7K | 9.9K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.37 |
| EPS | ★ N/A | N/A |
| Revenue | $16,296,958.00 | ★ $21,618,000.00 |
| Revenue This Year | N/A | $28.81 |
| Revenue Next Year | N/A | $70.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.48 |
| 52 Week Low | $2.05 | $4.11 |
| 52 Week High | $7.33 | $9.72 |
| Indicator | VERU | ELWT |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 61.14 |
| Support Level | $2.12 | $6.57 |
| Resistance Level | $2.67 | $9.58 |
| Average True Range (ATR) | 0.14 | 0.51 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 65.75 | 57.75 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.